Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

Spyre Therapeutics reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003 in patients with moderately-to-severely active ulcerative colitis. The favorable clinical readout supports development of the investigational extended half-life anti-IL-23 antibody and is likely to be a positive catalyst for SYRE shares, although specific efficacy and safety metrics were not disclosed.